Skip to content
Screener

Revvity RVTY Life Sciences — Segment Cost of Revenue

Similar metrics at other companies

STERIS logo
STELife Sciences: — Cost of Revenue
$65.6M+7.7%
Ashland logo
ASHLife Sciences — Cost Of Revenue
$106M+2.9%
VAT
VATELife Sciences — Cost of revenue
$1.4M-39.1%
Donaldson Company logo
DCILife Sciences Segment — Cost of Sales
$49.2M+7.9%
Thermo Fisher Scientific logo
TMOLife Sciences Solutions — Cost of revenues
$1B+17.4%
STERIS logo
STELife Sciences: — Revenue
$145.8M+6.9%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$12.83B+28.7%
Enterprise value$15.91B+28.6%
P/E53.5×+18.6×
P/S4.4×+0.9×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentCostOfRevenue.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000031791-26-000019
Line itemApril 5, 2026 / Life SciencesApril 5, 2026 / DiagnosticsApril 5, 2026 / TotalMarch 30, 2025 / Life SciencesMarch 30, 2025 / DiagnosticsMarch 30, 2025 / Total
Segment revenue$361,845$349,273$711,118$340,395$324,367$664,762
Segment cost of revenue131,574156,753119,321135,190
Segment selling, general and administrative expenses94,66890,19287,09489,891
Segment research and development expenses31,62426,20628,26925,271
Segment operating income$103,979$76,122180,101$105,711$74,015179,726
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's life sciences — segment cost of revenue?
Revvity (RVTY) reported life sciences — segment cost of revenue of $131.57M in Q1 2026.
How has Revvity's life sciences — segment cost of revenue changed year-over-year?
Revvity's life sciences — segment cost of revenue increased by 10.3% year-over-year, from $119.32M to $131.57M.
What is the long-term trend for Revvity's life sciences — segment cost of revenue?
Over 3 years (2022 to 2025), Revvity's life sciences — segment cost of revenue has grown at a 7.2% compound annual growth rate (CAGR), from $418.83M to $516.3M.
What does life sciences — segment cost of revenue mean?
The direct costs associated with producing and delivering the products and services sold by the Life Sciences segment. This includes raw materials, direct labor, and manufacturing overheads.

Ask your AI about Revvity's life sciences — segment cost of revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude